A clinical study of Silmitasertib for patients with covid-19 pneumonia requiring supplemental oxygen
Latest Information Update: 18 Sep 2020
At a glance
- Drugs Silmitasertib (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- 18 Sep 2020 New trial record
- 11 Sep 2020 According to a Senhwa Biosciences media release, the first patient was discharged from the hospital five days after starting Silmitasertib.
- 11 Sep 2020 According to a Senhwa Biosciences media release, the Food and Drug Administration (FDA) approved the first emergency IND and authorized use of Silmitasertib in a patient with severe COVID-19 pneumonia requiring supplemental oxygen for use in the COVID patient treated at BUMCP.